First Light Asset Management LLC Makes New $9.72 Million Investment in Spyglass Pharma, Inc. $SGP

First Light Asset Management LLC acquired a new stake in shares of Spyglass Pharma, Inc. (NASDAQ:SGP) in the first quarter, HoldingsChannel.com reports. The fund acquired 375,000 shares of the company’s stock, valued at approximately $9,716,000.

Separately, Monashee Investment Management LLC bought a new stake in Spyglass Pharma during the 1st quarter valued at $2,461,000.

Spyglass Pharma Price Performance

Shares of SGP opened at $20.49 on Monday. The stock has a market cap of $685.04 million and a PE ratio of -3.20. Spyglass Pharma, Inc. has a twelve month low of $17.06 and a twelve month high of $32.44. The firm’s fifty day moving average price is $19.82.

Spyglass Pharma (NASDAQ:SGP) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.67) by ($0.02).

Spyglass Pharma Company Profile

We are a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. Our mission is to significantly improve the lives of patients with chronic eye conditions by developing durable drug delivery solutions that can empower patients and surgeons with confidence in long-term disease control and vision preservation. Our lead product candidate, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), comprising novel, proprietary drug pads attached to our intraocular lens (IOL), is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients who have either open-angle glaucoma (OAG) or ocular hypertension (OHT).